SCHEDULE 13G/A 0002005369-25-000046 0002005369 XXXXXXXX LIVE 1 Class A Common Stock, $0.01 par value per share 09/30/2025 0001641489 vTv Therapeutics Inc. 918385204 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 Rule 13d-1(c) Invus Public Equities, L.P. D0 345926.00 0.00 345926.00 0.00 345926.00 N 8.4 PN Invus Public Equities Advisors, LLC DE 345926.00 0.00 345926.00 0.00 345926.00 N 8.4 OO Invus Global Management, LLC DE 345926.00 0.00 345926.00 0.00 345926.00 N 8.4 OO Siren, L.L.C. DE 345926.00 0.00 345926.00 0.00 345926.00 N 8.4 OO Avicenna Life Sci Master Fund LP E9 47172.00 0.00 47172.00 0.00 47172.00 N 1.2 PN Avicenna Life Sci Master GP LLC DE 47172.00 0.00 47172.00 0.00 47172.00 N 1.2 OO Ulys, L.L.C. DE 47172.00 0.00 47172.00 0.00 47172.00 N 1.2 OO Raymond Debbane R1 393098.00 0.00 393098.00 0.00 393098.00 N 9.4 IN vTv Therapeutics Inc. 3980 Premier Dr, Suite 310, High Point, NC 27265 See Item 2(c) below. See Item 2(c) below. (i) Invus Public Equities, L.P. ("Invus Public Equities") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Invus Global Management, LLC ("Global Management") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iv) Siren, L.L.C. ("Siren") c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (v) Avicenna Life Sci Master Fund LP ("Avicenna Fund") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Cayman Islands limited partnership (vi) Avicenna Life Sci Master GP LLC ("Avicenna GP") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (vii) Ulys, L.L.C. ("Ulys") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (viii) Mr. Raymond Debbane 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Panama The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Y Each of the Reporting Persons may be deemed to be the beneficial owner of the shares of Class A Common Stock (the "Shares") listed on such Reporting Person's cover page. As of September 30, 2025, (i) Invus Public Equities directly held (x) 143,440 Shares, (y) 29,523 Issuer Pre-Funded Warrants exercisable for Shares on a one-for-one basis ("Pre-Funded Warrants") and (z) 172,963 Issuer warrants to purchase one Share or a Pre-Funded Warrant in lieu of Shares ("Common Warrants," and together with the Pre-Funded Warrants, the "Warrants"), and (ii) Avicenna Fund directly held (x) 19,560 Shares, (y) 4,026 Pre-Funded Warrants and (z) 23,586 Common Warrants. Each of the Pre-Funded Warrants has an exercise price of $0.01 per Share and no expiration date, and each of the Common Warrants has an exercise price of $22.71 per Share or $22.70 per Pre-Funded Warrant and an expiration date of September 3, 2030. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own. As of September 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on (i) 3,938,018 Shares outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025, plus (ii) 230,098 Shares issuable upon exercise of the Warrants. See each cover page hereof. See each cover page hereof. See each cover page hereof. See each cover page hereof. Y Y Y Y Y N Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Invus Public Equities, L.P. /s/ Raymond Debbane 11/12/2025 Invus Public Equities Advisors, LLC /s/ Raymond Debbane 11/12/2025 Invus Global Management, LLC /s/ Raymond Debbane 11/12/2025 Siren, L.L.C. /s/ Raymond Debbane 11/12/2025 Avicenna Life Sci Master Fund LP /s/ Raymond Debbane 11/12/2025 Avicenna Life Sci Master GP LLC /s/ Raymond Debbane 11/12/2025 Ulys, L.L.C. /s/ Raymond Debbane 11/12/2025 Raymond Debbane /s/ Raymond Debbane 11/12/2025